March 4th, 2011
13th Annual Echocardiography Conference: State-of-the-Art 2011
CardioExchange Editors, Staff
NEJM — Recent Cardiology Articles- The COBRRA Trial — Ending the Venous Thromboembolism Safety Toss-up March 12, 2026The landscape of treatment options for venous thromboembolism was transformed by the arrival of direct oral anticoagulants. Large-scale trials showed that the direct oral anticoagulants apixaban and rivaroxaban were noninferior to vitamin K antagonists in terms of efficacy and had a better safety profile. However, for over a decade, a...
- Case 8-2026: A 57-Year-Old Woman with Chest Pain, Dyspnea, and Syncope March 12, 2026A 57-year-old woman was evaluated because of 2 days of chest pain and dyspnea. Ultrasonography showed a pericardial effusion with diastolic inversion of the right ventricle. A diagnosis was made.
- Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism March 12, 2026In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.
- Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome March 5, 2026A CD19-targeted therapy induced remission in a woman with refractory immune thrombocytopenia and antiphospholipid syndrome by stabilizing platelet counts, eliminating pathogenic antibodies, and enabling safer long-term anticoagulation.
- Assessing Nonculprit Coronary-Artery Lesions in STEMI March 5, 2026Multivessel coronary artery disease is seen on invasive coronary angiography in approximately 50% of patients presenting with acute ST-segment elevation myocardial infarction (STEMI). Previous trials have shown that in patients with hemodynamically stable disease, revascularization with percutaneous coronary intervention (PCI) of a nonculprit coronary lesion results in better outcomes than...
- The COBRRA Trial — Ending the Venous Thromboembolism Safety Toss-up March 12, 2026